



# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	106	Application Number	10/535,571
		Filing Date	May 19, 2005
		First Named Inventor	Kadyk
		Art Unit	
		Examiner Name	
		Attorney Docket Number	Ex 03-089C-US

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Document copies Return Receipt Postcard
<b>Remarks</b>  		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Exelixis, Inc.		
Signature			
Printed Name	Laleh Shayesteh		
Date	August 30, 2005	Reg. No.	47,937

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Laleh Shayesteh	Date	August 30, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Kadyk *et al.*  
Application No.: 10/535,571  
Filed: May 19, 2005  
For: MAPKS AS MODIFIERS OF THE  
RAC, AXIN, AND BETA CATENIN  
PATHWAYS AND METHODS OF  
USE

Confirmation No.: 8822  
Art Unit: Not Assigned  
Examiner: Not Assigned  
Attorney Docket No.: EX03-089C-US

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicant states that citation number 35 contained in the attached PTO Form 1449 was first cited in the International Search Report (copy attached) from the International Searching Authority in the counterpart PCT application.


In accordance with 37 C.F.R. §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R. §1.97 (h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any required fees, if necessary, to Deposit No. 50-1108.

Respectfully submitted,

Dated: August 30, 2005

  
\_\_\_\_\_  
Laleh Shayesteh Reg. No. 47,937  
Tel: (650) 837-8223; Fax: (650) 837-8234



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of Kadyk *et al.*  
Application No.: 10/535,571  
Filed: May 19, 2005  
For: MAPKS AS MODIFIERS OF THE RAC,  
AXIN, AND BETA CATENIN  
PATHWAYS AND METHODS OF USE

Confirmation No.: 8822  
Art Unit: Not Assigned  
Examiner: Not Assigned  
Attorney Docket No.: EX03-089C-US

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:


WO0129197, RIGEL PHARMACEUTICALS, INC., 2001-04-26  
WO9953036, SUGEN, INC., 1999-10-21  
US6277979, SmithKline Beecham plc, 2001-08-21  
WO0175067, HYSEQ, INC., 2001-10-11  
WO02055664, EXELIXIS, INC., 2002-07-18  
WO02079492, PROTEIN DESIGN LABS, INC., 2002-10-10  
WO0058473, CURAGEN CORPORATION, 2000-10-05  
WO0157190, HYSEQ, INC., 2001-08-09  
WO0233099, INCYTE GENOMICS, INC., 2002-04-25

The above-references have **not** been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: August 30, 2005

  
Laleh Shayesteh Reg. No. 47,937  
Tel: (650) 837-8223; Fax: (650) 837-8234



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 4

**Complete if Known**

Application Number	10/535,571
Filing Date	May 19, 2005
First Named Inventor	Kadyk
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-089C-US

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	International Human Genome Sequencing Consortium. Homo sapiens KIAA0551 protein (KIAA0551), mRNA. GI:22041067 03-JAN-2003	
	2	Nagase, T., et al. Homo sapiens mRNA for KIAA0551 protein, partial cds. GI:20521082 10-MAY-2002	
	3	Kawakami, T., et al. Homo sapiens cDNA: FLJ22817 fis, clone KAIA3476, highly similar to AF172271 Homo sapiens Traf2 and NCK interacting kinase splice variant 8 (TNIK) mRNA. GI:10439341 13-SEP-2003	
	4	Fu, C.A., et al. Homo sapiens Traf2 and NCK interacting kinase, splice variant 3 (TNIK) mRNA, complete cds. GI:6110351 25-OCT-1999	
	5	Fu, C.A., et al. Homo sapiens Traf2 and NCK interacting kinase, splice variant 5 (TNIK) mRNA, complete cds. GI:6110356 25-OCT-1999	
	6	Fu, C.A., et al. Homo sapiens Traf2 and NCK interacting kinase, splice variant 6 (TNIK) mRNA, complete cds. GI:6110359 25-OCT-1999	
	7	Fu, C.A., et al. Homo sapiens Traf2 and NCK interacting kinase, splice variant 7 (TNIK) mRNA, complete cds. GI:6110361 25-OCT-1999	
	8	Fu, C.A., et al. Homo sapiens Traf2 and NCK interacting kinase, splice variant 8 (TNIK) mRNA, complete cds. GI:6110364 25-OCT-1999	
	9	Strausberg, R. Homo sapiens, clone IMAGE:4651684, mRNA, partial cds. GI:17512195 11-DEC-2001	
	10	Fu, C.A., et al. Homo sapiens Traf2 and NCK interacting kinase, splice variant 2 (TNIK) mRNA, complete cds. GI:6110349 25-OCT-1999	
	11	Strausberg, R.L., et al. Homo sapiens TRAF2 and NCK interacting kinase, mRNA (cDNA clone IMAGE:4838784), complete cds. GI:33416309 28-JUL-2005	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

**Complete if Known**

Application Number	10/535,571
Filing Date	May 19, 2005
First Named Inventor	Kadyk
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-089C-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	12	Wright, J.H., et al. Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), transcript variant 1, mRNA. GI:22035601 20-DEC-2003	
	13	Yao, Z., et al. Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), mRNA. GI:4758523 01-NOV-2000	
	14	NCBI Annotation Project. Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), mRNA. GI:18553055 06-FEB-2002	
	15	Ishikawa, K., et al. Homo sapiens mRNA for KIAA0687 protein, partial cds. GI:3327187 06-FEB-1999	
	16	Bahr, A., et al. Homo sapiens mRNA; cDNA DKFZp434A025 (from clone DKFZp434A025). GI:6808458 16-APR-2005	
	17	Kawabata, A., et al. Homo sapiens cDNA: FLJ21957 fis, clone HEP05344. GI:10438179 13-SEP-2003	
	18	Ota, T., et al. Homo sapiens cDNA FLJ10410 fis, clone NT2RP1000018, highly similar to Homo sapiens mRNA for KIAA0687 protein. GI:7022424 30-JAN-2004	
	19	Wright, J.H., et al. Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), transcript variant 2, mRNA. GI:22035603 21-DEC-2003	
	20	Wright, J.H., et al. Homo sapiens mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4), transcript variant 3, mRNA. GI:22035605 21-DEC-2003	
	21	Dan, I., et al. Homo sapiens Misshapen/NIK-related kinase (MINK), mRNA. GI:7657334 10-DEC-2001	
	22	Strausberg, R.L., et al. Homo sapiens misshapen-like kinase 1 (zebrafish), transcript variant 3, mRNA (cDNA clone MGC:21111 IMAGE:4384442), complete cds. GI:21961594 09-JUL-2005	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/535,571		
		Filing Date	May 19, 2005		
		First Named Inventor	Kadyk		
		Art Unit			
		Examiner Name			
Sheet	3	of	4	Attorney Docket Number	EX03-089C-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	23	Dan,I., et al. Homo sapiens CHRNE, MINK genes for AchR epsilon subunit, GCK family kinase, partial cds. GI:21321027 03-JUL-2002	
	24	Ota,T., et al. Homo sapiens cDNA FLJ39291 fis, clone OCBBF2012436, highly similar to Homo sapiens mRNA for Misshapen/NIK-related kinase MINK-1. GI:21756143 30-JAN-2004	
	25	Hu,Y., et al. Homo sapiens misshapen-like kinase 1 (zebrafish) (MINK1), transcript variant 1, mRNA. GI:27436915 25-AUG-2005	
	26	Hu,Y., et al. Homo sapiens misshapen-like kinase 1 (zebrafish) (MINK1), transcript variant 3, mRNA. GI:27436916 25-AUG-2005	
	27	Hu,Y., et al. Homo sapiens misshapen-like kinase 1 (zebrafish) (MINK1), transcript variant 2, mRNA. GI:27436918 25-AUG-2005	
	28	International Human Genome Sequencing Consortium. Homo sapiens similar to NIK-related kinase (LOC203447), mRNA. GI:20549227 28-APR-2003	
	29	NCI-CGAP. on05g09.y5 NCI_CGAP_Kid3 Homo sapiens cDNA clone IMAGE:1555840 5' similar to TR:O60298 O60298 KIAA0551 PROTEIN ;, mRNA sequence. GI:5340679 13-DEC-1999	
	30	Lauber,J., et al. Homo sapiens mRNA; cDNA DKFZp686A17109 (from clone DKFZp686A17109); complete cds. GI:31874847 17-APR-2005	
	31	Fu,C.A., et al. Traf2 and NCK interacting kinase, splice variant 2 [Homo sapiens]. GI:6110350 25-OCT-1999	
	32	Beausoleil,S.A., et al. mitogen-activated protein kinase kinase kinase kinase 4 isoform 1 [Homo sapiens]. GI:22035602 23-APR-2005	
	33	Hu,Y., et al. misshapen/NIK-related kinase isoform 1 [Homo sapiens]. GI:7657335 25-AUG-2005	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4 of 4

**Complete if Known**

Application Number	10/535,571
Filing Date	May 19, 2005
First Named Inventor	Kadyk
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-089C-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	34	International Human Genome Sequencing Consortium. similar to NIK-related kinase [Homo sapiens]. GI:20549228 28-APR-2003	
	35	MacDonald T et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nature Genetics 29:143-152. 2001	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.